This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Dow 30 Stock Roundup: Bell-Boeing JV's Navy Deal Win, Merck Keytruda's Priority Review
by Swarup Gupta
The Dow traverses a holiday-shortened week during which trading volumes remain low.
Rite Aid (RAD) Stock Picks Momentum: Will It Scale Higher?
by Zacks Equity Research
Rite Aid (RAD) gathers momentum on pending merger with Albertsons, the sale of assets to Walgreens, lesser debt burden and a robust outlook.
Amazon Forays Into Pharmacy Business: Red Alert for Others?
by Sweta Jaiswal
Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.
Will Healthcare Buck Up on Amazon's Pillpack Takeover Deal?
by Sapna Bagaria
Amazon's (AMZN) use of technology, innovative strategies and skilled leadership should take it far in the healthcare space.
NKE Beats Earnings, Spotify's Video Push, & AMZN's Big Pharma Purchase
by Madeleine Johnson
On today's episode of the Zacks Friday Finish Line, Editor Maddy Johnson is joined by Ben Rains, an Associate Stock Strategist here at Zacks, to take on this week's biggest stories, including Nike's latest quarterly earnings results, Spotify's media ambitions, and Amazon's latest assault on the healthcare industry.
Dow 30 Stock Roundup: Nike, Walgreens Earnings Impress
by Swarup Gupta
The Dow endured a turbulent week, marked by lingering trade tensions.
After a Historic Rise, Should You Still Buy Amazon (AMZN) Stock?
by Afrasiab Mian
With massive growth already baked into its stock price, many investors may feel that Amazon stock is too expensive and that they have missed their chance to cash in. Is this truly the case? Let's take a look.
Investors Shouldn't Panic About Amazon's PillPack Purchase
by Benjamin Rains
Shares of pharmacy giants CVS (CVS), Rite Aid (RAD), and Walgreens Boots Alliance (WBA) all plummeted on Thursday morning after Amazon (AZMN) announced its purchase of online pharmacy delivery startup PillPack. The move clearly has some investors worried that Amazon's push into the pharmaceutical industry will hurt the current powers. So let's take a look at more of the details to find out what's really going on.
Walgreens (WBA) Tops Q3 Earnings Estimates, Narrows View
by Zacks Equity Research
Walgreens Boots (WBA) is upbeat about the recent acquisition of stores from Rite Aid which has already started to strengthen its U.S. pharmacies business.
WBA Enters The Dow, Q1 GDP Disappoints
by Zacks Equity Research
WBA Enters The Dow, Q1 GDP Disappoints
Walgreens Stumbles onto Dow, Futures Down
by Mark Vickery
We see negative sentiment for Walgreens based on news this morning that Amazon (AMZN) is buying its way into the retail pharma space.
Rite Aid (RAD) Reports Q1 Loss, Stock Up on Revenue Beat
by Zacks Equity Research
Rite Aid (RAD) reports first-quarter fiscal 2019 results, with the bottom line lagging estimates. However, the stock is witnessing increased momentum from the pending merger with Albertsons.
Walgreens Boots (WBA) Tops Q3 Earnings, Revenues Estimates
by Zacks Equity Research
Walgreens Boots' (WBA) third quarter 2018 results were encouraging on account of the company's strategic tie-ups which brought more patients to its U.S. pharmacies.
Rite Aid-Albertsons Deal: US SEC Sanctions Proxy Materials
by Zacks Equity Research
Rite Aid (RAD) is moving closer to completing its previously announced merger with Albertsons. The company's shareholders are going to cast their votes regarding the deal on Aug 9.
Will Walgreens (WBA) Q3 Earnings Gain From Overall Strength?
by Zacks Equity Research
Walgreens Boots' (WBA) sales rise at the Retail Pharmacy USA segment on account of tie-ups along with strength in other businesses buoys optimism.
RAD vs. WBA Which is a Better Stock Ahead of Earnings?
by Gourav Kanti Bagchi
Both Rite Aid and Walgreens Boots Alliance are scheduled to report earnings results on Jun 27 and Jun 28, respectively.
Why Is General Electric (GE) Stock Surging Today?
by Ryan McQueeney
Shares of General Electric (GE) gained about 8% in early morning trading Tuesday after the struggling multinational conglomerate announced plans to spin off its health-care business and separate its stake in Baker Hughes (BHGE) over the next few years.
WBA Replaces GE In The Dow
by Zacks Equity Research
WBA Replaces GE In The Dow
GE Leaves Dow, Trades Up 6.5%; Plus Housing News
by Mark Vickery
General Electric is trading up higher than 6.5% in today's pre-market on new headlines that the long-beleaguered firm will be spinning off its healthcare business and exiting its position on oil & gas company Baker Hughes.
Upcoming Earnings Reports to Watch: BBBY, WBA, NKE
by Ryan McQueeney
It is still a relatively quiet stretch for earnings reports, but the upcoming week should provide a few more reports for these investors to latch on to. Make sure to keep an eye on these companies as they prepare to report during the week of June 25!
News From This Week's Trending Stocks: AMZN, SBUX, CRON, GE, & More
by Ryan McQueeney
Ryan McQueeney and Maddy Johnson take on this week's biggest stories, including General Electric's (GE) departure from the Dow, Canada's marijuana legalization vote, the new tax policies affecting Amazon (AMZN), and many more!
Dow 30 Stock Roundup: Disney Ups Bid for Fox Assets, Boeing Wins $6.6B FedEx Contract
by Swarup Gupta
The Dow traversed a difficult week, declining over every single trading session.
With the Retail Sector Hot, Check out these Payment Processors
by David Borun
Increasing retail sales means more transaction-based profits for these payment firms
Walgreens-GE Faceoff: How Impactful is it for Dow Investors?
by Urmimala Biswas
The stock performance of Walgreens Boots (WBA) currently does not offer much conviction. Over the past year, shares show a decline of 17.9%.
Walgreens Boots (WBA) in Focus: Stock Moves 5.3% Higher
by Zacks Equity Research
Walgreens Boots (WBA) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.